Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
- Disease/Condition
- Chronic Obstructive Pulmonary Disease (COPD)
- Drug/Device/Intervention
- RESP Biosensor
- Study type
- Observational
- Intervention type
- device
- Primary sponsor
- Strados Labs, Inc.
- Location
- Philadelphia,Philadelphia, United States of America
- Phase
- N/A
- Start date
- Mar 15, 2023
- End date
- Dec 30, 2023
- Enrollment
- 0 participants
Statistically significant associations between RESP Biosensor-acquired lung findings and 1) subjective measure of respiratory symptoms measured by validated measurements tools and 2) home spirometry
Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians
 in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic
 testing to admit, follow and discharge patients from hospital. Of these, only auscultation
 routinely ceases upon discharge from Hospital. Healthcare utilization statistics have shown
 that for more than a decade, readmission after discharge for an exacerbation of COPD or
 severe asthma (or chronic heart failure) remains a major problem. The Strados RESP Biosensor
 has been designed to extend the range of lung sound recording both geographically and
 temporally to improve the standard of care when access to continuous monitoring has been
 replaced by periodic or no monitoring. The primary purpose of this study is to assess the
 associations between RESP Biosensor-acquired lung findings and subjective measures of
 respiratory symptoms as measured by validated measurement tools, and objective measure of
 respiratory physiology as determined by home spirometry
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05661435
- Type
- Device Trial
Access comprehensive clinical trial information for NCT05661435 through Pure Global AI's free database. This phase not specified trial is sponsored by Strados Labs, Inc. and is currently Withdrawn. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.